{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T19:28:08Z","timestamp":1777836488979,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Addict Res"],"published-print":{"date-parts":[[2019]]},"abstract":"<b><i>Background and objective:<\/i><\/b> Opioid maintenance treatment (OMT) is highly available in Norway, but only 50% of opioid-dependent individuals are enrolled in such programs. This study was aimed at examining if availability of extended-release naltrexone (XR-NTX) could attract individuals who for different reasons were not enrolled in an OMT program. <b><i>Methods:<\/i><\/b> In a Norwegian clinical study, <i>n<\/i> = 117 opioid-dependent adults volunteered to receive XR-NTX in a 9-month period, as an extension of a previous randomized clinical trial. <b><i>Results:<\/i><\/b> Before study inclusion, 40.2% (<i>n<\/i> = 47) of the study participants were not enrolled in OMT while the remainder were recruited from OMT. Participants not enrolled in OMT displayed more ongoing severe addiction-related problems such as heroin use (<i>p<\/i> = 0.002), but displayed a higher retention in treatment in the 9-month extension study (<i>p<\/i> = 0.048 for log-rank test) than participants enrolled in OMT. <b><i>Conclusion:<\/i><\/b> Availability of XR-NTX attracted opioid-dependent individuals not previously enrolled in OMT. While OMT may be perceived as a burden with regard to daily intake and control measures, one-monthly injections with XR-NTX may be perceived favourable, offering more freedom to the patients, not having addictive properties, and potentially reducing heroin craving. We suggest that an introduction of XR-NTX in Europe may increase the number of opioid-dependent individuals in treatment.<\/jats:p>","DOI":"10.1159\/000501931","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T21:00:34Z","timestamp":1564002034000},"page":"303-309","source":"Crossref","is-referenced-by-count":10,"title":["Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial"],"prefix":"10.1159","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-2947","authenticated-orcid":false,"given":"Kristin\u00a0Klemmetsby","family":"Solli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4530-2021","authenticated-orcid":false,"given":"Nikolaj","family":"Kunoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zill-E-Huma","family":"Latif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamni","family":"Sharma-Haase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arild","family":"Opheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Krajci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanna","family":"Gaulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u016brat\u0117","family":"\u0160altyt\u0117\u00a0Benth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Tanum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2019,7,24]]},"container-title":["European Addiction Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/501931","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/501931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:46:46Z","timestamp":1745423206000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000501931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":0,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,11,6]]},"published-print":{"date-parts":[[2019,11,12]]}},"URL":"https:\/\/doi.org\/10.1159\/000501931","archive":["Portico"],"relation":{},"ISSN":["1022-6877","1421-9891"],"issn-type":[{"value":"1022-6877","type":"print"},{"value":"1421-9891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}